A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression

A Six-Week, Randomized, Double-Blind, Multicenter, Fixed-Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients With Bipolar I Depression

This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.

Study Overview

• Status: Completed
• Conditions: Bipolar Disorder
• Intervention / Treatment: Drug: Geodon (Ziprasidone); Drug: Geodon (Ziprasidone); Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 536
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35209
      • Pfizer Investigational Site
  • California
    • Dana Point, California, United States, 92629
      • Pfizer Investigational Site
    • La Mesa, California, United States, 91942
      • Pfizer Investigational Site
    • Laguna Hills, California, United States, 92653
      • Pfizer Investigational Site
    • Oceanside, California, United States, 92056
      • Pfizer Investigational Site
    • Orange, California, United States, 92868
      • Pfizer Investigational Site
    • San Diego, California, United States, 92108
      • Pfizer Investigational Site
    • San Diego, California, United States, 92120
      • Pfizer Investigational Site
    • Santa Ana, California, United States, 92705
      • Pfizer Investigational Site
    • Torrance, California, United States, 90505
      • Pfizer Investigational Site
  • Florida
    • Fort Lauderdale, Florida, United States, 33319
      • Pfizer Investigational Site
    • Gainesville, Florida, United States, 32607
      • Pfizer Investigational Site
    • Hialeah, Florida, United States, 33016
      • Pfizer Investigational Site
    • Jacksonville, Florida, United States, 32216
      • Pfizer Investigational Site
    • North Miami, Florida, United States, 33161
      • Pfizer Investigational Site
    • Orlando, Florida, United States, 32806
      • Pfizer Investigational Site
    • Winter Park, Florida, United States, 32789
      • Pfizer Investigational Site
  • Georgia
    • Atlanta, Georgia, United States, 30308
      • Pfizer Investigational Site
  • Illinois
    • Maywood, Illinois, United States, 60153
      • Pfizer Investigational Site
    • Naperville, Illinois, United States, 60563
      • Pfizer Investigational Site
    • Schaumburg, Illinois, United States, 60194
      • Pfizer Investigational Site
  • Indiana
    • Greenwood, Indiana, United States, 46143
      • Pfizer Investigational Site
    • Lafayette, Indiana, United States, 47905
      • Pfizer Investigational Site
  • Kansas
    • Prarie Village, Kansas, United States, 66206
      • Pfizer Investigational Site
  • Louisiana
    • New Orleans, Louisiana, United States, 70114
      • Pfizer Investigational Site
    • Shreveport, Louisiana, United States, 71101
      • Pfizer Investigational Site
    • Shreveport, Louisiana, United States, 71105
      • Pfizer Investigational Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Pfizer Investigational Site
    • Worcester, Massachusetts, United States, 01605
      • Pfizer Investigational Site
  • Minnesota
    • Minneapolis, Minnesota, United States, 55454
      • Pfizer Investigational Site
  • Mississippi
    • Flowood, Mississippi, United States, 39232
      • Pfizer Investigational Site
  • Missouri
    • Saint Louis, Missouri, United States, 63128
      • Pfizer Investigational Site
    • Saint Louis, Missouri, United States, 63144
      • Pfizer Investigational Site
  • Nebraska
    • Omaha, Nebraska, United States, 68131
      • Pfizer Investigational Site
  • Nevada
    • Las Vegas, Nevada, United States, 89102
      • Pfizer Investigational Site
  • New Jersey
    • Clementon, New Jersey, United States, 08021
      • Pfizer Investigational Site
    • Toms River, New Jersey, United States, 08755
      • Pfizer Investigational Site
  • New York
    • New York, New York, United States, 10021
      • Pfizer Investigational Site
    • Staten Island, New York, United States, 10305
      • Pfizer Investigational Site
  • Ohio
    • Cincinnati, Ohio, United States, 45267-0001
      • Pfizer Investigational Site
    • Cleveland, Ohio, United States, 44106
      • Pfizer Investigational Site
    • Cleveland, Ohio, United States, 44113
      • Pfizer Investigational Site
    • Mayfield, Ohio, United States, 44143
      • Pfizer Investigational Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73118
      • Pfizer Investigational Site
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19131
      • Pfizer Investigational Site
    • Philadelphia, Pennsylvania, United States, 19149
      • Pfizer Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15213
      • Pfizer Investigational Site
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Pfizer Investigational Site
    • Columbia, South Carolina, United States, 29201
      • Pfizer Investigational Site
  • Tennessee
    • Memphis, Tennessee, United States, 38119
      • Pfizer Investigational Site
    • Nashville, Tennessee, United States, 37203-1515
      • Pfizer Investigational Site
  • Texas
    • Bellaire, Texas, United States, 77401
      • Pfizer Investigational Site
    • Dallas, Texas, United States, 75216
      • Pfizer Investigational Site
    • Dallas, Texas, United States, 75234
      • Pfizer Investigational Site
    • DeSoto, Texas, United States, 75115
      • Pfizer Investigational Site
    • Galveston, Texas, United States, 77555-0188
      • Pfizer Investigational Site
    • Houston, Texas, United States, 77555
      • Pfizer Investigational Site
    • Irving, Texas, United States, 75062
      • Pfizer Investigational Site
    • Plano, Texas, United States, 75093
      • Pfizer Investigational Site
    • Richardson, Texas, United States, 75080
      • Pfizer Investigational Site
    • San Antonio, Texas, United States, 78229
      • Pfizer Investigational Site
    • San Antonio, Texas, United States, 78284-7792
      • Pfizer Investigational Site
    • Wichita Falls, Texas, United States, 76309
      • Pfizer Investigational Site
  • Virginia
    • Arlington, Virginia, United States, 22201
      • Pfizer Investigational Site
    • Falls Church, Virginia, United States, 22041
      • Pfizer Investigational Site
    • Richmond, Virginia, United States, 23229
      • Pfizer Investigational Site
    • Richmond, Virginia, United States, 23230
      • Pfizer Investigational Site
    • Virginia Beach, Virginia, United States, 23452
      • Pfizer Investigational Site
  • Washington
    • Kirkland, Washington, United States, 98033
      • Pfizer Investigational Site
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Pfizer Investigational Site
    • Milwaukee, Wisconsin, United States, 53227
      • Pfizer Investigational Site
    • West Allis, Wisconsin, United States, 53227
      • Pfizer Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode depressed, with or without rapid cycling, without psychotic features, as defined in Diagnostic and Statistical Manual (of Mental Disorders) - Fourth Edition - Text Revision (DSM-IV-TR) (296.5X) and confirmed by a structured Mini International Neuropsychiatric Interview (MINI)

Exclusion Criteria:

• Subjects with a DSM-IV TR diagnosis of schizophrenia (295.XX), schizoaffective disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or psychotic disorder not otherwise specified (298.9).
• Subjects with other DSM-IV TR Axis I or Axis II disorder (in addition to Bipolar I disorder) are ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6 month period prior to screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
Active Comparator: 20-40mg BID arm	Drug: Geodon (Ziprasidone); Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial; Drug: Geodon (Ziprasidone); Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
Active Comparator: 60-80mg bid arm	Drug: Geodon (Ziprasidone); Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial; Drug: Geodon (Ziprasidone); Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score	Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. MADRS is 10-item instrument measuring depression; scale 0(Normal) and 6(most abnormal). Total possible score is 0 - 60.	Baseline to 6 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response Greater Than or Equal to 50 Percent Decrease From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score	Participants with MADRS Total Score greater or equal to 50 percent decrease from baseline responded yes; others responded no. Endpoint is last observation carried forward (LOCF) among Week 1 - Week 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6 (most abnormal). Total possible score is 0 - 60	Baseline to 6 weeks
Response Greater Than or Equal to 50 Percent Decrease From Baseline in Hamilton Depression Rating Scale (HAM-D 17) Total Score	Participants with greater than or equal to 50 percent decrease from baseline in HAMD-17 total score responded yes; others responded no. Endpoint is LOCF endpoint among Week 1 - 6; Total score is first 17 items of HAM-D 25: measures range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52.	Baseline to 6 weeks
Change in Global Assessment of Functioning (GAF)at Endpoint, Last Observation Carried Forward (LOCF)	Change is observed value at endpoint minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 - 6; GAF is used to assess global psychological, social, & occupational functioning; 100=normal and 0=greatest abnormality	Baseline, 6 Weeks LOCF
Remission as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than or Equal to 12	Response was Yes if MADRS Total Score was less than, equal to 12, if not, response was no. Endpoint is LOCF endpoint among Week 1 through 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6(most abnormal)	Baseline to 6 weeks
Remission as Measured by Hamilton Depression (HAM-D 17) Total Score Less Than or Equal to 7	Response was yes when HAM-D 17 total score was less than or equal to 7 , if not, response was no. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25,which measures the range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52.	Baseline to 6 weeks
Change in Hamilton Depression (HAM-D 17) Total Score	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25, which measures the range of depressive symptoms patient currently experiencing; scale 0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme. Total possible score 0 - 52.	Baseline to 6 weeks
Change in Hamilton Anxiety Rating (HAM-A)	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. HAM-A is a 14-item scale: rates intensity of psychic anxiety and somatic anxiety on a 5-point severity scale (range: 0=not present to 4=very severe). Total possible score is 0 - 56.	Baseline to 6 weeks
Change in Total Score of Young Mania Rating Scale (YMRS)	Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. YMRS: 11 item instrument with scale 0 to 4 for 7 items and 0 to 8 for 4 items; 0=normal; 4 or 8=most abnormal. Total possible score is 0 - 60.	Baseline to 6 weeks
Change in Assessment of Global Clinical Severity of Symptoms (CGI-S)	Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-S measures severity of patient's mental illness. Scale range: 0 = not assessed, 1 = normal, 7 = among most extremely ill	Baseline to 6 weeks
Change in Global Clinical Improvement of Symptoms (CGI -I)	Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-I is an instrument for Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse	Baseline to 6 weeks
Change in Total Score in Hamilton Depression (HAM-D 25)	Change: observed value at each visit minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 through Week 6. HAM-D 25: measures the range of depressive symptoms experienced. 25 Items with Scale range:0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme.Total possible score is 0 - 72.	Baseline to 6 Weeks
Response as Measured by CGI-I Score Less Than or Equal to 2	Response each week was yes if CGI-I score less than or equal to 2 (much or very much improved), if not, response was no; Endpoint is LOCF endpoint among Week 1 through Week 6. CGI-I is a Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse	Week 1 through Week 6 (endpoint)
Change in Sheehan Disability Scale (SDS) Total Score at Endpoint	Observed value each visit minus baseline value. Endpoint is LOCF Week 1 through Week 6. SDS: patient rated measure of disability and impairment in 3 items: work/school, social life, family life/home responsibilities:0(no disruption)- 10(extreme disruption). Total possible is 30.	Baseline to Week 6
Change in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Total Score at Endpoint	Change is observed value at each visit minus baseline value. LOCF endpoint among Week 1 through Week 6. Q-LES-Q: 16-item instrument for patients assessment of his/her quality of life; overall level of satisfaction scale 1=very poor to 5=Very good (1 item re medication can be blank). Total possible score 15 - 80	Baseline to 6 Weeks
Change in Bech Melancholia Score	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Bech Melancholia is the sum of Scores on 6 Items pertaining to melancholia within Hamilton Depression Rating Scale (HAM-D). Scale 0 to 4, higher scores reflecting greater severity;Total possible 0 - 24.	Baseline to 6 Weeks
Change in Anxiety/Somatizations Factor Total Score	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores on 6 Items measuring anxiety/somatization within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4, higher scores reflecting greater severity. Total possible 0 - 24.	Baseline to 6 Weeks
Change in Retardation Factor Scores	Change is observed value at each visit minus baseline value. This instrument = sum of Scores of 4 items on retardation within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 16.	Baseline to 6 Weeks
Change in Sleep Disturbance Factor Score	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores of 3 items on sleep disturbance within Hamilton Depression Rating Scale (HAM-D). Scale range 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 12.	Baseline to 6 weeks
Change in Verbal Memory Trial Performance Total Score at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is part of Brief Assessment of Cognition and measures recall of 15 words repeated 5 times. Range 0-75 words, higher number reflects better recall.	Baseline to 6 Weeks LOCF
Change in Affective Interference Test Immediate Recall List 1 Emotional Words at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition measuring immediate recall of 15 emotional words; higher number of words is better recall.	Baseline to 6 Weeks LOCF
Change in Affective Interference Test Immediate Recall Non-Emotional Words List 1 at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument measures immediate recall of 15 non-emotional words (List 1); higher number of words is better recall.	Baseline to 6 Weeks LOCF
Change in Affective Interference Test, Immediate Recall, List 2 Emotional Words at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is in Brief Assessment of Cognition and measures immediate recall of 15 emotional words (List 2); higher number of words is better recall	Baseline to 6 Weeks LOCF
Change in Affective Interference Test, Immediate Recall, List 2 Non-Emotional Words at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 2); higher number of words is better recall	Baseline to 6 Weeks LOCF
Change in Affective Interference Test, Immediate Recall, List 3 Emotional Words at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 emotional words (List 3); higher number of words is better recall	Baseline to Week 6 LOCF
Change in Affective Interference Test, Immediate Recall, List 3 Non-Emotional Words at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 3); higher number of words is better recall	Baseline to Week 6 LOCF
Change in Affective Interference Test, Immediate Recall, Cued-Recall Non-Emotional Words at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 non-emotional words; higher number of words is better recall	Baseline to 6 Weeks LOCF
Change in Affective Interference Test, Immediate Recall, Cued-Recall Emotional Words at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 emotional words; higher number of words is better recall	Baseline to 6 Weeks LOCF
Change in Digit Sequencing Task at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which patient sequences digits from lowest to highest. Range of number of correct responses (0-28); higher numbers show better digit sequencing and greater cognition.	Baseline to 6 Weeks LOCF
Change in Token Motor Task at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which a patient places as many of 100 tokens (2 at a time) into a container as they can within 60 seconds. The higher number of tokens placed = patient is better at motor tasks	Baseline to 6 Weeks LOCF
Change in Verbal Fluency in Naming Categories at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition.Patients are given 60 seconds to name as many words as possible within a given category. The more words named=better cognition.	Baseline to 6 Weeks LOCF
Change in Verbal Fluency Controlled Word Association at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. Patients given 60 seconds to generate as many words as possible that begin with a given letter; better verbal fluency = more words	Baseline to 6 Weeks LOCF
Change in Symbol Coding at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. For 90 seconds, Patient writes numerals 1-9 as matched to symbols. Range 0 to 110 with higher totals = better cognition.	Baseline to 6 Weeks LOCF
Change in Tower of London Test at Endpoint	Change is observed value at each visit minus baseline value. Endpoint: LOCF endpoint among Week 1 through Week 6. Brief Assessment of Cognition: subjects asked to arrange balls in 2 pictures so they are identical and give the total number of ball movements to reach this arrangment. Range: 0-22; more correct = better cognition.	Baseline to 6 Weeks LOCF
Change in Affective Interference Test, Delayed Recognition, Emotional Words at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition in which the number of correct emotional words in delayed recognition is measured. Range 0-75 with higher numbers showing better cognition.	Baseline to 6 Weeks LOCF
Change in Affective Interference Test, Delayed Recognition, Emotional Words False Alarms at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition which measures number of correct emotional word's false alarms (during delayed recognition). Higher number = better cognition	Baseline to 6 Weeks LOCF
Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of Non-Emotional Words (Delayed Recognition); higher number of words = better cognition	Baseline to Week 6 LOCF
Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words False Alarms at Endpoint	Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of correct non-eEmotional word's false alarms(at delayed recognition). Higher number of words = greater cognition	Baseline to Week 6 LOCF

Collaborators and Investigators

• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Publications and helpful links

General Publications

• Keefe RS, Fox KH, Davis VG, Kennel C, Walker TM, Burdick KE, Harvey PD. The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls. J Affect Disord. 2014 Sep;166:86-92. doi: 10.1016/j.jad.2014.05.002. Epub 2014 May 11.
• Gao K, Pappadopulos E, Karayal ON, Kolluri S, Calabrese JR. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol. 2013 Jun;33(3):425-31. doi: 10.1097/JCP.0b013e3182917f3f.

Study record dates

Study Major Dates

• Study Start: July 1, 2005
• Primary Completion (Actual): February 1, 2008
• Study Completion (Actual): February 1, 2008

Study Registration Dates

• First Submitted: August 30, 2005
• First Submitted That Met QC Criteria: August 30, 2005
• First Posted (Estimate): September 1, 2005

Study Record Updates

• Last Update Posted (Actual): March 25, 2021
• Last Update Submitted That Met QC Criteria: March 2, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Keywords: Bipolar I Disorder
• Additional Relevant MeSH Terms: Mental Disorders; Bipolar and Related Disorders; Bipolar Disorder; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Serotonin Agents; Dopamine Agents; Serotonin Antagonists; Dopamine Antagonists; Ziprasidone
• Other Study ID Numbers: A1281136

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No